Boston Globe | A Great Day And A Great Future For Alnylam Seeking Alpha Currently, the only treatment options for early stage FAP disease are liver transplantation and tafamidis (approved in Europe). The mean survival for familial amyloidotic cardiomyopathy (FAC) patients is approximately 2.5 years, and there are no ... Alnylam Reports Positive Top-Line Results for ALN-TTRsc, a Subcutaneously ... |
